The patient remains on continuous osimertinib therapy with durable disease control at the time of manuscript preparation.<h4>Conclusion</h4>Primary <i>EGFR T790M</i>-positive NSCLC can achieve durable disease control with first-line osimertinib, even in advanced age. Here, EGFR is linked to non-small cell lung carcinoma.